Satellos Bioscience Inc.
No enriched coverage for $MSLE in the last 7 days.
No SEC Form 4 filings for $MSLE in the last 30 days.
A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.
Satellos Bioscience (NASDAQ:MSLE) reported early results for SAT-3247 in its TRAILHEAD adult DMD study. In four participants, biceps brachii muscle fat fraction improved 3.7 points (49.7% to 46.0%) by day 140, with TE99c rising about 34% and creatine kinase down 38%. BASECAMP readout is expected in Q4.
Satellos Bioscience (NASDAQ: MSLE, TSX: MSCL) reported six-month interim TRAILHEAD data for SAT-3247 in four adults with Duchenne muscular dystrophy. Mean muscle fat fraction fell 3.7% (49.7% to 46.0%), TE99C effort rose about 34% (16.1 to 21.6 J/kg), CK fell 38% (2130 to 1315 u/l), and safety was favorable. A call is scheduled July 8.
Recent MSLE coverage spans technology, market movers and financial news.
Interim efficacy and safety signals in a Phase 2 trial can improve perceived disease-modifying potential and trial credibility.
Early adult DMD biomarker and functional signals for SAT-3247 strengthen the probability of progressing to BASECAMP and support FDA engagement for accelerated approval discussions.
Interim, small-sample efficacy and biomarker improvements with favorable tolerability may support risk-on positioning ahead of BASECAMP readouts.
The initiation of coverage by Leerink Partners with an 'Outperform' rating and a $20 target price suggests positive market sentiment towards Satellos Bioscience Inc. (MSLE). The bullish analyst outlook may lead to increased investor interest and upward price movement in the near term.
alphai scores every news story that mentions MSLE with an AI model for sentiment and relevance, and aggregates insider trades from Satellos Bioscience Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.
3 min readSatellos Bioscience (NASDAQ:MSLE) reported early results for SAT-3247 in its TRAILHEAD adult DMD study. In four participants, biceps brachii muscle fat fraction improved 3.7 points (49.7% to 46.0%) by day 140, with TE99c rising about 34% and creatine kinase down 38%. BASECAMP readout is expected in Q4.
4 min readSatellos Bioscience (NASDAQ: MSLE, TSX: MSCL) reported six-month interim TRAILHEAD data for SAT-3247 in four adults with Duchenne muscular dystrophy. Mean muscle fat fraction fell 3.7% (49.7% to 46.0%), TE99C effort rose about 34% (16.1 to 21.6 J/kg), CK fell 38% (2130 to 1315 u/l), and safety was favorable. A call is scheduled July 8.
6 min readInvestment bank Leerink Partners has initiated coverage on Satellos Bioscience Inc. (MSLE) with an "Outperform" rating and a $20 target price. This positive outlook by analysts highlights the biotechnology company's innovative technology platform. The report aims to provide professional research references for investors interested in Satellos Bioscience.
2 min read
